Alnylam Pharmaceuticals (ALNY) Weakness is Buying Opportunity, Says Deutsche Bank

February 14, 2014 2:18 PM

Deutsche Bank reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a price target of $108.00. Analyst Alethia Young ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found